Anti-argonaute2 (Ago2/Su) and -Ro antibodies identified by immunoprecipitation in primary anti-phospholipid syndrome (PAPS)

References

• Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RHPG DEG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4 2: 295–306.
   PubMed Web of Science ®Google Scholar
• Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quere I, Hachulla E, Vasconcelos C, Roch B, Fernandez-Nebro A, Boffa MC, Hughes GR, Ingelmo M. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1.000 patients. Arthritis Rheum. 2002; 46 4: 1019–1027.
   PubMed Web of Science ®Google Scholar
• Cervera R, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Kiss E, Zeher MM, Tincani A, Kontopoulou-Griva I, Galeazzi M, Bellisai F, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quere I, Hachulla E, Vasconcelos C, Roch B, Fernandez-Nebro A, Piette JC, Espinosa G, Bucciarelli S, Pisoni CN, Bertolaccini ML, Boffa MC, Hughes GR. Morbidity and mortality in the anti-phospholipid syndrome during a 5-year period; a multicentre prospective study of 1.000 patients. Ann Rheum Dis. 2009; 68 9: 1428–1432.
   PubMed Web of Science ®Google Scholar
• Ames PR, Antinolfi I, Ciampa A, Batuca J, Scenna G, Lopez LR, Delgado Alves J, Iannaccone L, Matsuura E. Primary antiphospholipid syndrome: A low-grade auto-inflammatory disease?. Rheumatology (Oxford). 2008; 47 12: 1832–1837.
   PubMed Web of Science ®Google Scholar
• Grossman JM. Primary versus secondary antiphospholipid syndrome: Is this lupus or not?. Curr Rheumatol Rep. 2004; 6 6: 445–450.
   PubMedGoogle Scholar
• McClain MT, Arbuckle MR, Heinlen LD, Dennis GJ, Roebuck J, Rubertone MV, Harley JB, James JA. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum. 2004; 50 4: 1226–1232.
   PubMedGoogle Scholar
• Ruffatti A, Del Ross T, Ciprian M, Nuzzo M, Rampudda M, Bertero MT, Bergia R, Caramaschi P, Biasi D, Capsoni F, Montaguti L, Ruffini R, Brucato A, Picillo U, Fanelli V, Riccieri V, Piccoli A, Valesini G, Doria A, Meroni PL, Tincani A. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A muticentre, retrospective follow-up study. Ann Rheum Dis. 2009; 68 3: 397–399.
   PubMed Web of Science ®Google Scholar
• Asherson RA, Cervera R, Lahita RG. Latent, incomplete or lupus at all?. J Rheumatol. 1991; 18 12: 1783–1786.
   PubMed Web of Science ®Google Scholar
• Gomez-Puerta JA, Martín H, Amigo MC, Aguirre MA, Camps MT, Cuadrado MJ, Hughes GR, Khamashta MA. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: Do they develop lupus?. Medicine (Baltimore). 2005; 84 4: 225–230.
   PubMed Web of Science ®Google Scholar
• Danieli MG, Fraticelli P, Franceschini F, Cattaneo R, Farsi A, Passaleva A, Pietrogrande M, Invernizzi F, Vanoli M, Scorza R, Sabbadini MG, Gerli R, Corvetta A, Farina G, Salsano F, Priori R, Valesini G, Danieli G. Five-year follow-up of 165 Italian patients with undifferentiated connective tissue diseases. Clin Exp Rheumatol. 1999; 17 5: 585–591.
   PubMed Web of Science ®Google Scholar
• Mosca M, Neri R, Bencivelli W, Tavoni A, Bombardieri S. Undifferentiated connective tissue disease: Analysis of 83 patients with a minimum followup of 5 years. J Rheumatol. 2002; 29 11: 2345–2349.
   PubMed Web of Science ®Google Scholar
• Andreoli L, Pregnolato F, Burlingame RW, Fanelli V, Allegri F, Radice A, Corace C, Sinico RA, Tincani A, Meroni PL. Primary antiphospholipid syndrome evolving into systemic lupus erythematosus: May anti-nucleosome antibodies be predictive?. Reumatismo. 2008; 60 3: 185–191.
   PubMedGoogle Scholar
• Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25 11: 1271–1277.
   PubMed Web of Science ®Google Scholar
• Derksen RH, Gmelig-Meijling FH, de Groot PG. Primary antiphospholipid syndrome evolving into systemic lupus erythematosus. Lupus. 1996; 5 1: 77–80.
   PubMed Web of Science ®Google Scholar
• Mackworth-Young C. Primary antiphospholipid syndrome: A distinct entity?. Autoimmun Rev. 2006; 5 1: 70–75.
   PubMed Web of Science ®Google Scholar
• Weber M, Hayem G, De Bandt M, Seifert B, Palazzo E, Roux S, Kahn MF, Meyer O. Classification of an intermediate group of patients with antiphospholipid syndrome and lupus-like disease: Primary or secondary antiphospholipid syndrome?. J Rheumatol. 1999; 26 10: 2131–2136.
   PubMed Web of Science ®Google Scholar
• Tincani A, Biasini-Rebaioli C, Cattaneo R, Riboldi P. Nonorgan specific autoantibodies and heart damage. Lupus. 2005; 14 9: 656–659.
   PubMed Web of Science ®Google Scholar
• Satoh M, Langdon JJ, Chou C-H, McCauliffe DP, Treadwell EL, Ogasawara T, Hirakata M, Suwa A, Cohen PL, Eisenberg RA, Reeves WH. Characterization of the Su antigen, a macromolecular complex of 100/102 and 200-kDa proteins recognized by autoantibodies in systemic rheumatic diseases. Clin Immunol Immunopathol. 1994; 73 1: 132–141.
   PubMedGoogle Scholar
• Jakymiw A, Ikeda K, Fritzler MJ, Reeves WH, Satoh M, Chan EK. Autoimmune targeting of key components of RNA interference. Arthritis Res Ther. 2006; 8 4: R87.
   Web of Science ®Google Scholar
• Tincani A, Allegri F, Sanmarco M, Cinquini M, Taglietti M, Balestrieri G, Koike T, Ichikawa K, Meroni P, Boffa MC. Anticardiolipin antibody assay: A methodological analyses for a better consensus in routine determinations; a cooperative project of the European Antiphosholipid Forum. Thromb Haemost. 2001; 86 2: 575–583.
   PubMed Web of Science ®Google Scholar
• Balestrieri G, Tincani A, Spatola L, Allegri F, Prati E, Cattaneo R, Valesini G, Del Papa N, Meroni P. Anti-beta 2-glycoprotein I antibodies: A marker of antiphospholipid syndrome?. Lupus. 1995; 4 2: 122–130.
   PubMed Web of Science ®Google Scholar
• Yamasaki Y, Narain S, Hernandez L, Barker T, Ikeda K, Segal MS, Richards HB, Chan EK, Reeves WH, Satoh M. Autoantibodies against the replication protein A complex in systemic lupus erythematosus and other autoimmune diseases. Arthritis Res Ther. 2006; 8 4: R111–R120.
   PubMed Web of Science ®Google Scholar
• Eystathioy T, Chan EK, Tenenbaum SA, Keene JD, Griffith K, Fritzler MJ. A phosphorylated cytoplasmic autoantigen, GW182, associates with a unique population of human mRNAs within novel cytoplasmic speckles. Mol Biol Cell. 2002; 13 4: 1338–1351.
   PubMed Web of Science ®Google Scholar
• Satoh M, Vázquez-Del Mercado M, Chan EK. Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol. 2009; 19:219–228.
   PubMed Web of Science ®Google Scholar
• Satoh M, Treadwell EL, Reeves WH. Pristane induces high levels of anti-Su and anti-nRNP/Sm autoantibodies in BALB/c mice. Quantitation by antigen capture ELISAs based on monospecific human autoimmune sera. J Immunol Meth. 1995; 182:51–62.
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Twig G, Katz U, Sherer Y. Autoantibody explosion in anti-phospholipid syndrome. J Autoimmun. 2008; 30:74–83.
   PubMed Web of Science ®Google Scholar
• Treadwell EL, Alspaugh MA, Sharp GC. Characterization of a new antigen-antibody system(Su) in patients with systemic lupus erythematosus. Arthritis Rheum. 1984; 27:1263–1271.
   PubMedGoogle Scholar
• Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature. 2004; 431 7006: 343–349.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Sankala H, Zhang X, Graves PR. Phosphorylation of Argonaute 2 at serine-387 facilitates its localization to processing bodies. Biochem J. 2008; 413 3: 429–436.
   PubMedGoogle Scholar
• Ikeda K, Satoh M, Pauley KM, Fritzler MJ, Reeves WH, Chan EK. Detection of the argonaute protein Ago2 and microRNAs in the RNA induced silencing complex (RISC) using a monoclonal antibody. J Immunol Meth. 2006; 317 1–2: 38–44.
   PubMed Web of Science ®Google Scholar
• Azuma-Mukai A, Oguri H, Mituyama T, Qian ZR, Asai K, Siomi H, Siomi MC. Characterization of endogenous human Argonautes and their miRNA partners in RNA silencing. Proc Natl Acad Sci USA. 2008; 105 23: 7964–7969.
   PubMed Web of Science ®Google Scholar
• Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005; 52 5: 1491–1503.
   PubMed Web of Science ®Google Scholar
• Zhuang H, Narain S, Sobel E, Lee PY, Nacionales DC, Kelly KM, Richards HB, Segal M, Stewart C, Satoh M, Reeves WH. Association of anti-nucleoprotein autoantibodies with upregulation of Type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus. Clin Immunol. 2005; 117 3: 238–250.
   PubMed Web of Science ®Google Scholar
• Marshak-Rothstein A, Rifkin IR. Immunologically active autoantigens: The role of toll-like receptors in the development of chronic inflammatory disease. Annu Rev Immunol. 2007; 25:419–441.
   PubMed Web of Science ®Google Scholar
• Kelly KM, Zhuang H, Nacionales DC, Scumpia PO, Lyons R, Akaogi J, Lee P, Williams B, Yamamoto M, Akira S, Satoh M, Reeves WH. “Endogenous adjuvant” activity of the RNA components of lupus autoantigens Sm/RNP and Ro 60. Arthritis Rheum. 2006; 54 5: 1557–1567.
   PubMedGoogle Scholar
• Gantier MP, Tong S, Behlke MA, Xu D, Phipps S, Foster PS, Williams BR. TLR7 is involved in sequence-specific sensing of single-stranded RNAs in human macrophages. J Immunol. 2008; 180 4: 2117–2124.
   PubMed Web of Science ®Google Scholar
• Reed JH, Jackson MW, Gordon TP. Ro 60 functions as a receptor for beta(2)-glycoprotein I on apoptotic cells. Arthritis Rheum. 2009; 60 3: 860–869.
   PubMedGoogle Scholar
• Manfredi AA, Rovere P, Galati G, Heltai S, Bozzolo E, Soldini L, Davoust J, Balestrieri G, Tincani A, Sabbadini MG. Apoptotic cell clearance in systemic lupus erythematosus. I. Opsonization by antiphospholipid antibodies. Arthritis Rheum. 1998; 41:205–214.
   PubMed Web of Science ®Google Scholar
• Manfredi AA, Rovere P, Heltai S, Galati G, Nebbia G, Tincani A, Balestrieri G, Sabbadini MG. Apoptotic cell clearance in systemic lupus erythematosus. II. Role of β2glycoprotein I. Arthritis Rheum. 1998; 41:215–223.
   PubMed Web of Science ®Google Scholar
• Fatenejad S, Mamula MJ, Craft J. Role of intermolecular/intrastructural B and T-cell determinants in the diversification of autoantibodies to ribonucleoprotein particles. Proc Natl Acad Sci U S A. 2010; 90:12010–12014.
   Google Scholar
• Nahid MA, Pauley KM, Satoh M, Chan EK. miR-146a is critical for endotoxin-induced tolerance: implication in innate immunity. J Biol Chem. 2009; 284 50: 34590–34599.
   PubMed Web of Science ®Google Scholar
• Chan EK, Satoh M, Pauley KM. Contrast in aberrant microRNA expression in systemic lupus erythematosus and rheumatoid arthritis: Is microRNA-146 all we need?. Arthritis Rheum. 2009; 60:912–915.
   PubMedGoogle Scholar
• Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune disease. J Autoimmun. 2009; 32:189–194.
   PubMed Web of Science ®Google Scholar